RDC.DE stock plunged -21.01% to €47.00 at market close after Redcare Pharmacy N.V. reported FY25 results and commentary that left traders uncertain. The move came on a volume spike of 896,005 shares versus an average of 91,665, signalling a fast reposition by investors. Redcare showed revenue growth but mixed margins and a slowdown in OTC sales that weighed on the share price. We summarise the key earnings figures, valuation metrics, technical levels and what the Meyka AI grade and forecasts imply for traders on XETRA in Germany.

RDC.DE stock: earnings snapshot and price action

Redcare Pharmacy N.V. reported FY25 revenue of €2.94 billion, up 24.06%, while net losses narrowed to -€37.70 million, an improvement of 17.08% year-over-year. The company confirmed the earnings announcement timing and investors reacted sharply, pushing the XETRA-listed shares to a session low of €45.92 and closing at €47.00.

Traders sold heavily after management flagged an OTC slowdown despite a prescription surge, driving a 1‑day change of -21.01% with relative volume near 9.77x the norm source. A broader market note also recorded the stock among the biggest decliners on the session source.

RDC.DE stock: financials and margins

Top line strength is clear: revenue per share TTM is 138.57 and FY25 revenue rose to €2.94 billion, but profitability remains fragile with EPS at -1.76 and a negative net profit margin of -1.25%. Free cash flow per share is -2.53, and operating cash flow per share is 1.61, indicating cash generation is smaller than the headline revenue growth.

Balance-sheet metrics show book value per share at 25.64 and cash per share of 13.33, while debt-to-equity is 0.78, which leaves room but requires watchfulness as management navigates margin pressures and OTC category weakness.

RDC.DE stock: valuation and technicals

Valuation is mixed: price-to-sales is 0.43, price-to-book is 2.41, and trailing PE is negative at -26.70 reflecting losses. The stock trades below its 50-day average €64.22 and 200-day average €78.43, arguing the market has repriced the company on near-term risks.

Technicals show RSI 39.04 and oversold momentum indicators (CCI -101.58, Williams %R -82.86). Key technical support sits at the year low €45.92 and immediate resistance at the 50-day band near €64.22. Short-term traders should note the high relative volume of 896,005 shares.

Meyka AI rates RDC.DE with a score out of 100 and forecast

Meyka AI rates RDC.DE with a score out of 100: 71.61 | Grade: B+ | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects revenue growth, improved FY25 losses and our model’s sensitivity to margin recovery.

Meyka AI’s forecast model projects a range of outcomes. The monthly projection is €70.25 (+49.47% vs €47.00), the quarterly projection is €36.44 (-22.51%), and the yearly projection is €94.92 (+101.90%). Forecasts are model-based projections and not guarantees.

RDC.DE stock: risks, opportunities and sector context

Key risks include continued OTC slowdown, thin near-term profitability, and negative free cash flow per share of -2.53. Interest coverage is negative at -1.27, so a sustained margin weakness could pressure liquidity.

Opportunities include secular prescription demand across Germany and other EU markets, strong revenue growth of 24.06% in FY25, and a low price-to-sales ratio of 0.43 versus some healthcare peers. In the healthcare sector, average P/E is about 30.20, so Redcare’s current pricing reflects operational stress rather than market multiples.

RDC.DE stock: trading strategy and price targets

For traders we outline a short-term defensive approach: set a stop-loss below €45.92 and watch for volume-confirmed support to re-establish positions. A conservative intra-quarter price target aligned with our quarterly forecast is €36.44, while a recovery scenario target for 12 months is €94.92, implying significant upside if margins normalize.

Long-term investors should wait for sustained improvement in free cash flow and a return to positive EPS or clearer guidance on margin recovery before adding size. Remember the stock trades on XETRA in EUR and shows high short-term volatility.

Final Thoughts

RDC.DE stock finished the session down sharply on an earnings-driven re-rating that prioritised margin risks over top-line strength. Redcare Pharmacy N.V. delivered €2.94 billion in FY25 revenue and narrower losses, but an OTC slowdown and mixed cash flow left investors selling into the report. At €47.00, the stock sits below its 50-day and 200-day averages and near the year low €45.92, signalling that the market expects more clarity on profitability. Meyka AI’s forecast model projects a yearly level of €94.92, implying an upside of about 101.90% versus the current price, while a nearer-term quarterly projection of €36.44 implies downside of -22.51%. Our proprietary grade (B+ | 71.61) balances growth and operational risk, but forecasts are model-based projections and not guarantees. Investors should weigh the revenue momentum against cash flow deficits and sector peers, and monitor management guidance, OTC trends and trading volume before committing capital. For an up-to-date dashboard and real-time alerts see the Meyka stock page for RDC.DE

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.